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The synthesis of 2’,2’-bis-benzylisoquinolines and their cytostatic 
activities 
 
Stephen R. Taylor, Alison T. Ung* and Stephen G. Pyne* 
 
Department of Chemistry, University of Wollongong, Wollongong, NSW, 2522, Australia 
 
Abstract: The novel laudanosine dimers in which two laudanosine units are linked via a 
C-2’ biaryl bond have been prepared by a sequence that involves formation of the biaryl 
bond first and then formation of the isoquinoline rings. Two of these compounds showed 
higher cytostatic activity on three cancer cell lines than thalicarpine. 
   
Over two hundred bisbenzylisoquinoline alkaloids are known, the majority of these have 
one or two ether linkages between the two benzylisoquinoline moieties.1  However, a 
number of these alkaloids have one of the linking ether bonds replaced by a biphenyl 
linkage.2  The bisbenzylisoquinoline alkaloids show a range of interesting biological 
activities.1  The related Thalictrum alkaloid, thalicarpine 1,3 comprises the 
benzylisoquinoline, S-laudanosine, connected via an ether linkage to an aporphine 
moiety.  This molecule was found to have significant biological activity against the 
Walker 256 carcinoma and antiproliferative activity on a broad range of human and 
animal cell lines in vitro and in vivo.4,5  Initial clinical trails on this compound appeared 
encouraging,4-9 however phase II clinical trials stopped after no antitumour effect was 
observed.7,9    
Inspired by the structure and biological activity of thalicarpine we became interested in 
the synthesis of the novel laudanosine dimers 2 and 3, in which two laudanosine units are 
linked via a C-2’ biaryl bond, and an examination of their cytotoxicities on cancer cell 
lines.  This paper describes the successful synthesis of rac- and meso-2 and a single 
diastereomer of 3 and their cytotostatic activities on three cancer cell lines. 
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Our initial approach to the target molecules 2 and 3 is shown in Scheme 1 and was based 
on an Ullmann coupling reaction of N-trifluoroacetyl-2’-iodonorlaudanosine 7, to deliver 
the desired bi-aryl coupled product.  The key compound 7 was prepared as shown in 
Scheme 1 from the known compound, 2-iodo-4,5-dimethoxyphenylacetic acid 410 as 
shown in Scheme 1, using standard procedures.  The Bischler-Napieralski cyclisation of 5 
was carried out efficiently using PCl5 in CH2Cl2 according to the procedure of 
Ziolkowski et al.11  Surprisingly the amide 5 has only been reported once and not in a 
readily accessible journal.12 The iodides 6 and 7 are new compounds, while the 
corresponding 2’-bromo analogues of these compounds are known.13 Heating compound 
7, or its corresponding 2’-bromo derivative, in the presence of copper-bronze at 220o C 
under solvent free conditions for 1.5 h lead to quantitative decomposition of the material 
and no recognisable products could be isolated. 
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An alternative and successful synthesis of 2 and 3 is shown in Scheme 3, this synthesis 
involved formation of the key biaryl bond early in the synthesis and then construction of 
the isoquinoline rings.  To this end several methods to prepare the known biphenyl 913-15 
were examined (Scheme 2).  Under traditional Ullmann coupling reaction conditions,13 
heating compound 8 in the presence of copper-bronze at 220o C under solvent free 
conditions for 1.5 h gave the desired biphenyl 9 in 69 % yield.  When the corresponding 
bromo analogue of 8 was employed the yield of 9 was reduced to 45 % due to the 
formation of the debromo-derivative 10.  Alternatively, the biphenyl 9 could be obtained 
by direct oxidative coupling of 10 using phenyliodotrifluoroacetate (PIFA)/BF3.Et2O in 
MeCN16 or molybdenum (V) chloride (MoCl5)
17/4Å molecular sieves (MS) in yields of 
41 and 55 %, respectively.   The latter method also produced the ring chlorinated product 
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11, which was the major product in the absence of a HCl scavenger.  For example, 
treatment of 10 with MoCl5 alone have 11 in 50% yield and the desired biphenyl 9 in <10 
% yield.  Although the addition of inorganic bases (NaHCO3, NaH2PO4 or Na2CO3) 
reduced the amount of 11 formed to 20-40% the yield of the desired biphenyl 9 was still 
relatively low (10-20%).  We found that the addition of 4Å MS to the reaction mixture 
worked the best and suppressed the formation of 11 to 10% yield. 
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The biphenyl 9 was then taken through to the bis-benzylisoquinoline 2 as shown in 
Scheme 3 using the chemistry described in Scheme 1.   The 1H NMR resonances 
attributed to the methylene protons α to the carbonyl group of the bis-amide 13 appeared 
as an ABq at  3.23 (JAB = 15.3 Hz). Presumably the presence of the adjacent biaryl axis 
made these methylene protons diastereotopic. The Bischler-Napieralski cyclisation of the 
the bis-amide 13 using PCl5 in CH2Cl2 gave the resulting bis-1,2-dihydro-isoquinoline 14 
that was immediately reduced with sodium borohydride to give 2 as a 2 : 1 mixture of 
diastereomers (rac-2 and meso-2, not necessarily respectively) in 67% yield.  The bis-
imine 14 was extremely unstable and if the Bischler-Napieralski cyclisation reaction was 
left for longer than 2 h at rt total decomposition occurred. An alternative cyclization 
procedure using triflic anhydride in the presence of DMAP was not successful.18 The 
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instability of symmetrical di-imines is not a new phenomenon,19 however even 
attempting sequential Bischler-Napieralkski cyclisation and reduction of each amide 
according to the method of Czarnocki19 failed to yield the desired compound. Whilst only 
a limited number of cyclization conditions were studied, the PCl5 cyclization conditions 
seemed to be the best for this application. 
The two isomers of 2 were readily separated by column chromatography and had NMR 
and ESI-MS spectral data consistent with their proposed structures.  The major 
diastereomer of 2 was converted to 3 by reductive N-methylation in excellent yield 
(Scheme 3). 
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Cytostaticity studies against the cancer cell lines, H460 (human non small cell lung), 
MCF-7 (human breast) and SF-268 (human CNS) were performed at the Peter 
MacCallum Cancer Institute, Melbourne using NCI protocols.  Initially the % cell growth 
of cells incubated with 25M of the compounds, thalicarpine 1, 2 (major diastereomer), 2 
(minor diastereomer) and 3. The results are presented in Table 1.  Compound 3 (Table 1, 
Entry 4) showed the weakest cyctostatic activity on all cell lines, while both the major 
and minor diastereomers of 2 (Table 1, Entries 2 and 3) showed stronger cytostatic 
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activity than thalicarpine (Entry 1).  The IC50 of the major isomer of 2 was determined to 
be > 40 M on the same three cell lines, which indicated it had only modest cytotoxictity.   
 
Table 1. Cytostatic studies on cancer cell lines. 
Entry Compound Percentage Cell Growth 
H460 MCF-7 SF-268 
1 1 15 63 54 
2 2 
(major) 
0.8 16.4  40.9 
3 2 
(minor) 
5.4 26.1 23.7 
4 3 95 131 78 
 
 
In conclusion, the novel laudanosine dimers 2 and 3, in which two laudanosine units are 
linked via a C-2’ biaryl bond have been prepared by a sequence that involves formation 
of the biaryl bond first and then formation of the isoquinoline rings. The rac- and meso-
forms of 2 were readily separated by column chromatography.  Compound 3 showed the 
weakest cyctostatic activity on 3 cancer cell lines, while both the major and minor 
diastereomers of 2 showed higher cytostatic activity than thalicarpine 1.   
 
 
EXPERIMENTAL  
PS refers to the fraction of petroleum spirit with a boiling point of 40-60 C.  All 1H 
NMR spectra were performed at 300 MHz and all 13C NMR (DEPT) spectra at 75 MHz 
in CDCl3 solution, unless otherwise noted. All spectra were referenced to CDCl3 (
1H  
7.26 ppm and 13C NMR  77.00 ppm). 1H NMR assignments were achieved with the aid 
of gCOSY, and in some cases NOESY and TOCSY experiments. 13C NMR assignments 
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were based upon DEPT, gHSQC and gHMBC experiments. Compounds 4,10 820 and 1021 
were prepared according to the literature.  
 
N-[2-(3,4-Dimethoxyphenyl)ethyl]-2-(2-iodo-4,5-dimethoxyphenyl)acetamide 5 
Compound 410 (1.11 g, 3.45 mmol), 2-[3,4-dimethoxyphenyl]ethylamine  (1.45 mL, 8.62 
mmol), HOBT (512 mg, 3.79 mmol) and EDCI (730 mg, 3.79 mmol) were dissolved in 
dry DMF (15 mL) under N2 and the solution was stirred for 18 h at rt. The mixture was 
diluted with H2O (30 mL) and extracted with CH2Cl2 (2 x 20 mL). The extracts were 
combined, washed with H2O (2 x 30 mL), dried (MgSO4), filtered and evaporated. The 
title compound was isolated as a white solid (1.44 g, 86 %) after purification by flash 
silica gel chromatography with CH2Cl2:EtOAc (3:1) as mobile phase. M.P. 176-178 
oC. 
1H NMR: δ 7.19 (s, 1H, Ar-H-3), 6.77 (s, 1H, Ar-H-6), 6.71 (d, 1H, J = 8.1 Hz, Ar-H-5’), 
6.64 (d, 1H, J = 2.1 Hz, Ar-H-2’), 6.58 (dd, 1H, J = 8.1, 2.1 Hz, Ar-H-6’), 5.41 (t, J = 6.9 
Hz, 1H, NH), 3.87 (s, 3H, OCH3-4), 3.85 (s, 3H, OCH3-4’), 3.84 (s, 3H, OCH3-3’), 3.82 
(s, 3H, OCH3-5), 3.60 (s, 2H, Ar-CH2), 3.47 (q, 2H, J = 6.9 Hz, Ar-CH2-CH2-NH), 2.71 
(t, 2H, J = 6.9, Ar-CH2-CH2-NH).
 13C NMR: δ 169.6 (C=O), 149.6 (Ar-C-OCH3-5), 
149.0 (Ar-C-OCH3-3’), 148.7 (Ar-C-OCH3-4), 147.6 (Ar-C-OCH3-4’), 130.9 (Ar-C-1), 
130.5 (Ar-C-1’), 121.6 (Ar-C-H-3), 120.5 (Ar-C-H-6’), 113.0 (Ar-C-H-6), 111.7 (Ar-C-
H-5’), 111.1 (Ar-C-H-2’), 88.8 (Ar-C-2), 56.1 (Ar-OCH3), 55.9 (Ar-OCH3), 55.84 (Ar-
OCH3), 55.81 (Ar-OCH3), 48.1 (Ar-CH2-CO), 40.6 (Ar-CH2-CH2-NH), 35.8 (Ar-CH2-
CH2-NH). MS (EI+): m/z 485 (M
+ 3 %), 164 (100 %), HRMS (EI+) Calcd for 
C20H24INO5 = 485.0699 (M
.+), found 485.0696. 
 
 
(R,S)-1-[(2-Iodo-4,5-dimethoxyphenyl)methyl]-6,7-dimethoxy-1,2,3,4-
tetrahydroisoquinoline 6 
PCl5 (107 mg, 0.51 mmol) was added to a stirred solution of 5 (100 mg, 0.21 mmol) in 
dry CH2Cl2 (5 mL) and the resulting mixture stirred for 18 h at rt under a N2 atmosphere. 
The solution was diluted with CH2Cl2 (10 mL), washed with sat. aqueous NaHCO3 (2 x 
20 mL), dried over MgSO4, filtered and evaporated. The resulting imine was dissolved in 
dry ice-cold MeOH (5 mL) and sodium borohydride (46 mg, 1.21 mmol) was added. The 
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ice bath was removed and the mixture stirred at rt for 1 h. The solvent was evaporated 
under reduced pressure and the residue dissolved in CH2Cl2 (10 mL). The solution was 
washed with saturated aqueous Na2CO3 solution (2 x 10 mL), dried (K2CO3), filtered and 
evaporated to yield the free amine as a white film (95 mg, 99 %) that did not require 
further purification. 1H NMR: δ 7.20 (s, 1H, Ar-H-3’), 6.72 (s, 1H, Ar-H-6’), 6.71 (s, 1H, 
Ar-H-5), 6.53 (s, 1H, Ar-H-8), 4.14 (dd, 1H, J = 9.6, 4.2 Hz, Ar-H-1), 3.79 (s, 6H, OCH3-
6, 7), 3.77 (s, 3H, OCH3-5’), 3.76 (s, 3H, OCH3-4’), 3.19 (dd, 1H, J = 14.1, 4.2 Hz, Ar-
CHa-CH-), 2.91-2.84 (m, 3H, Ar-CH2-CH2-NH, Ar-CHb-CH-), 2.70 (d, 2H, J = 12.9, 6.3, 
Ar-CH2-CH2-NH).  
13C NMR: δ 149.4 (Ar-C-OCH3-5’), 148.5 (Ar-C-OCH3-4’), 147.8 
(Ar-C-OCH3-7), 147.3 (Ar-C-OCH3-6), 134.1 (Ar-C-8a), 129.9 (Ar-C-4a), 127.2 (Ar-C-
1’), 122.0 (Ar-C-H-6’), 114.0 (Ar-C-H-3’), 111.9 (Ar-C-H-5), 109.9 (Ar-C-H-8), 89.0 
(Ar-C-2’), 56.4 (Ar-OCH3-6), 56.2 (Ar-OCH3-7), 56.1 (Ar-OCH3-5’), 56.0 (Ar-OCH3-
4’), 55.5 (C-1), 47.0 (Ar-CH-NH), 40.7 (Ar-CH2-CO, Ar-CH2-CH2-NH), 29.4 (Ar-CH2-
CH2-NH).  MS (EI+): m/z 469 (M
+ 6 %), 340 (100 %), HRMS (CI+) calcd for 
C20H25INO4 = 470.0828 (M+H
+), found 470.0825. 
 
(R,S)-1-[(2-Iodo-4,5-dimethoxyoxophenyl)methyl]-2-trifluoroacetyl-6,7-dimethoxy-
1,2,3,4-tetrahydroisoquinoline 7 
Compound 6 (95 mg, 0.20 mmol) was dissolved in dry pyridine (2 mL) and 
trifluoroacetic anhydride (1.5 mL) was added. The solution was stirred for 18 h at rt. The 
mixture was diluted and stirred with 1M HCl solution (10 mL) for 30 min, then extracted 
with CH2Cl2 (2 x 20 mL). The extracts were washed with sat. aqueous NaHCO3 solution 
(2 x 20 mL), dried (MgSO4), filtered and evaporated. Purification by flash silica gel 
chromatography with EtOAc:PS (1:1) as mobile phase yielded the title compound as an 
orange film (81 mg, 70 %). 1H NMR: δ 7.19 (s, 1H, Ar-H-3’), 6.65 (s, 1H, Ar-H-6’), 6.60 
(s, 1H, Ar-H-5), 6.52 (s, 1H, Ar-H-8), 5.71 (dd, 1H, J = 8.1, 6.3 Hz, H-1), 4.05-4.01 (m, 
1H, Ar-CH2-CHa-NCOCF3), 3.86 (s, 3H, OCH3-6), 3.84 (s, 3H, OCH3-7), 3.78 (s, 3H, 
OCH3-5’), 3.74 (s, 3H, OCH3-4’), 3.70 (d, 1H, J = 5.7 Hz, Ar-CH2-CHb-NCOCF3), 3.26 
(dd, 1H, J = 14.0, 6.3 Hz, Ar-CHa-CH), 3.25 (dd, 1H, J = 14.0, 8.1 Hz, Ar-CHb-CH), 
3.02-2.91 (m, 1H, Ar-CHa-CH2-NCOCF3), 2.79 (dt, 1H, J = 15.9, 3.9 Hz, Ar-CHb-CH2-
NCOCF3). 
13C NMR: δ (C=O not observed) 149.4 (Ar-C-OCH3-6), 148.7 (Ar-C-OCH3-
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5’), 148.5 (Ar-C-OCH3-7), 147.9 (Ar-C-OCH3-4’), 132.3 (Ar-C-1’), 126.6 (Ar-C-4a), 
125.1 (Ar-C-8a), 121.7 (Ar-C-H-3’), 116.8 (q, J = 284.1 Hz, NCOCF3), 113.1 (Ar-C-H-
6’), 111.2 (Ar-C-H-5), 110.4 (Ar-C-H-8), 89.8 (Ar-C-2’), 56.3 (Ar-OCH3-6), 56.2 (Ar-
OCH3-7), 56.1 (Ar-OCH3-5’), 56.0 (Ar-OCH3-4’), 54.5 (Ar-CH-NCOCF3), 45.6 (Ar-
CH2-CH2-NCOCF3), 40.4 (Ar-CH2-CH), 28.9 (Ar-CH2-CH2-NCOCF3). MS (EI+): m/z 
565 (M+ 4 %), 288 (100 %), HRMS (EI+) Calcd for C22H23IF3NO5 = 565.0573 (M
.+), 
found 565.0576. 
 
Dimethyl 2,2’-(4,4’,5,5’-tetramethoxybiphenyl-2,2’-diyl)diacetate 9 
Method 1: To a solution of 1021 (129 mg, 0.62 mmol) and PIFA (250 mg, 0.58 mmol) in 
dry MeCN (10 mL) at 0 oC under N2 was added BF3
.Et2O (150 μL). After 10 min the 
mixture was diluted with water (20 mL) and extracted with CH2Cl2 (2 x 20 mL). The 
extracts were combined, washed with sat. aqueous NaHCO3 (20 mL), dried (MgSO4), 
filtered and evaporated. Purification by flash silica gel chromatography using EtOAc:PS 
(3:7) as the eluent, yielded the title compound as clear crystals (53 mg, 41 %).  
Method 2: The title compound was also prepared in 55 % yield (clear crystals, 110 mg) 
by stirring 1021 (200 mg, 0.95 mmol) in dry CH2Cl2 (20 mL) with powdered molecular 
sieves (4 Ǻ, 500 mg) for 30 min and cooling the mixture to 0 oC. MoCl5 (570 mg, 2.11 
mmol) was added to the reaction mixture and stirring was continued at 0 oC for 2 h after 
which the mixture was diluted with water (15 mL) and extracted with DCM (2 x 20 mL). 
The extracts were combined, washed with sat. aqueous NaHCO3 (20 mL), dried 
(MgSO4), filtered and evaporated. Purification by flash silica gel chromatography using 
EtOAc:PS (3:7) as the eluent yielded the title compound.  
Method 3: The title compound was also prepared in 69 % yield (clear crystals, 172 mg) 
by heating 820 (200 mg, 0.60 mmol) with freshly activated copper-bronze22 (200mg) in a 
Wheaton vial at 220 oC for 1.5 h. The heat was removed and the mixture suspended in 
EtOAc (50 mL), filtered and the solvent evaporated. The title compound was purified by 
flash silica gel chromatography using EtOAc:PS (3:7) as the eluent.  
M.P. 142-144 oC (lit.20 M.P. 145 oC). 1H NMR:  6.84 (s, 2H, Ar-H-6), 6.72 (s, 2H, Ar-
H-3), 3.92 (s, 6H, OCH3-5), 3.83 (s, 6H, OCH3-4), 3.60 (s, 6H, CO2CH3), 3.35 (ABq, 4H, 
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J = 16.5 Ar-CH2). 
13C NMR:  172.4 (C=O), 148.1 (Ar-C-OCH3-4), 147.4 (Ar-C-OCH3-
5), 132.8 (Ar-C-1), 124.6 (Ar-C-2), 113.2 (Ar-C-H-3), 112.5 (Ar-C-H-6), 55.8 (Ar-
OCH3), 55.7 (Ar-OCH3), 51.8 (CO2CH3), 37.9 (Ar-CH2).  MS (CI+): m/z 419 (M+H, 100 
%), HRMS (EI+): Calcd for C22H26O8 = 418.1627 (M
.+), found 418.1615. 
 
 
2,2’-(4,4’,5,5’-Tetramethoxybiphenyl-2,2’-diyl)diacetic acid 12 
Compound 9 (150 mg, 0.36 mmol) was dissolved in methanol (2 mL) and added to a 40 
0C stirred solution of K2CO3 (99 mg, 0.72 mmol) in H2O (2 mL). After 2 h the reaction 
was removed from the heat and the methanol evaporated. The aqueous residue was 
acidified with 10 % aqueous HCl solution to pH 1, extracted with CH2Cl2 (2 x 20 mL), 
dried (MgSO4), filtered and evaporated to dryness to yield the title compound as a white 
solid (137 mg, 98 %). No further purification was required. M.P. 228-230 oC, lit.20 228-
230 oC. 1H NMR:  9.72 (bs, 1H, COOH), 6.77 (s, 1H, Ar-H-3), 6.60 (s, 1H, Ar-H-6), 
3.89 (s, 3H, OCH3-5), 3.82 (s, 3H, OCH3-4), 3.45 (ABq, 2H, J = 17.7 Ar-CH2-CO).  
13C NMR:  179.1 (C=O), 148.3 (Ar-C-OCH3-4), 147.7 (Ar-C-OCH3-5), 132.9 (Ar-C-1), 
124.5 (Ar-C-2), 113.1 (Ar-C-H-6), 112.8 (Ar-C-H-3), 55.9 (Ar-OCH3), 55.8 (Ar-OCH3), 
37.3 (Ar-CH2-COOH).  MS (ESI-): m/z 389 (M
-, 37 %), 114 (100 %), HRMS (ESI-): 
calcd for C20H21O8 = 389.1236 (M
-), found 389.1218.  
 
N,N’-Di-[2-(3,4-dimethoxyphenyl)ethyl]-2,2’-(4,4’,5,5’-tetramethoxybiphenyl-2,2’-
diyl)diacetamide 13 
The diacid 12 (130 mg, 0.33), 2-[3,4-dimethoxyphenyl]ethylamine (0.28 mL, 1.65 
mmol), HOBT (99 mg, 0.73 mmol) and EDCI (128 mg, 0.66 mmol) were dissolved in 
dry DMF (6 mL) under N2 and the solution was stirred for 18 h at RT. The mixture was 
diluted with H2O (30 mL) and extracted with CH2Cl2 (2 x 20 mL). The extracts were 
combined, washed with H2O (2 x 30 mL), dried (MgSO4), filtered and evaporated. The 
title compound was isolated as a white solid (214 g, 90 %) after purification by flash 
silica gel chromatography with CH2Cl2:EtOAc (3:1) as mobile phase. M.P. 162-164 
oC. 
1H NMR:  6.81 (s, 1H, Ar-H-3’), 6.72 (d, 1H, J = 8.1 Hz, Ar-H-5), 6.63 (d, 1H, J = 2.1 
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Hz, Ar-H-2), 6.58 (s, 1H, Ar-H-6’), 6.55 (dd, J = 8.1, 2.1 Hz, Ar-H-6), 5.78 (t, 1H, J = 
5.4 Hz, NH), 3.87 (s, 3H, OCH3-4’), 3.85 (s, 3H, OCH3-4), 3.81 (s, 3H, OCH3-3), 3.80 (s, 
3H, OCH3-5’), 3.35 (dt, 2H, J = 6.9, 5.4 Hz, Ar-CH2-CH2-NH), 3.23 (ABq, 2H, J = 15.3 
Ar-CH2-CO), 2.66 (t, 2H, J = 6.9, Ar-CH2-CH2-NH). 
13C NMR:  171.1 (C=O), 148.9 
(Ar-C-OCH3-5’), 148.5 (2x Ar-C-OCH3-4, 4’), 147.6 (Ar-C-OCH3-5), 132.6 (Ar-C-2’), 
131.0 (Ar-C-1), 125.7 (Ar-C-1’), 120.5 (Ar-C-H-6), 113.2 (Ar-C-H-6’), 112.4 (Ar-C-H-
3’), 111.6 (Ar-C-H-2), 111.1 (Ar-C-H-5), 56.0 (Ar-OCH3), 55.9 (Ar-OCH3), 55.8 (Ar-
OCH3), 55.7 (Ar-OCH3), 40.8 (Ar-CH2-CH2-NH), 40.6 (Ar-CH2-CO), 34.9 (Ar-CH2-
CH2-NH). MS (ES+): m/z 717 (M+H, 30 %), 288 (100 %), HRMS (ESI+): calcd for 
C40H49N2O10 = 717.3387 (MH
+), found 717.3402. 
 
 
 
 
(1RS,1’’’RS) and (1R,1’’’S)-2,2’-[Di-{(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-
1-yl)methyl}]-4,4’,5,5’-biphenyl 2 
PCl5 (87 mg, 0.42 mmol) was added to a stirred solution of compound 13 (50 mg, 0.07 
mmol) in dry CH2Cl2 (2 mL) and the resulting mixture stirred for 2 h at rt under a N2 
atmosphere. The solution was diluted with CH2Cl2 (10 mL), washed with sat. aqueous 
NaHCO3 (2 x 20 mL), dried (MgSO4), filtered and evaporated. The resulting imine was 
dissolved in dry ice-cold MeOH (5 mL) and sodium borohydride (8 mg, 0.2 mmol) was 
added. The ice bath was removed and the mixture stirred at rt for 1 h. The solvent was 
evaporated under reduced pressure and the residue dissolved in CH2Cl2 (10 mL). The 
solution was washed with saturated aqueous Na2CO3 solution (2 x 10 mL), dried 
(K2CO3), filtered and evaporated. The crude mixture was separated by column 
chromatography using CH2Cl2/EtOH/MeOH/NH3 (10 : 5 : 1 : 0.1) as the eluent. to yield 
pure samples of the major isomer as a white solid (20 mg, 42 %, Rf 0.2) and the minor 
isomer as a white solid (12 mg, 25 %, Rf 0.4); reflecting a combined yield of 67 % for 
both diastereomers. 
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Major isomer: 1H NMR: (the individual methoxy signals could not be assigned 
unequivocally)  6.94 (s, 1H, Ar-H-3’), 6.46 (s, 1H, Ar-H-6’), 6.26 (s, 1H, Ar-H-5), 6.05 
(s, 1H, Ar-H-8), 4.06-3.93 (m, 1H, H-1), 3.83 (s, 3H, OCH3), 3.75 (s, 3H, OCH3), 3.58 (s, 
3H, OCH3), 3.52 (s, 3H, OCH3), 3.26-3.16 (m, 2H, Ar-CH2-CH), 3.11-2.96 (m, 2H, Ar-
CH2-CH2-NH), 2.91-2.70 (m, 2H, Ar-CH2-CH2-NH).  
13C NMR:  148.7 (Ar-C-OCH3-
5’), 148.1 (Ar-C-OCH3-4’), 147.9 (Ar-C-OCH3-7), 147.4 (Ar-C-OCH3-6), 135.4 (Ar-C-
1’), 134.3 (Ar-C-2’), 133.0 (Ar-C-4a), 123.9 (Ar-C-8a), 113.9 (Ar-C-H-3’), 112.6 (Ar-C-
H-6’), 111.1 (Ar-C-H-8), 110.7 (Ar-C-H-5), 56.0 (Ar-OCH3), 55.8 (Ar-OCH3), 55.7 (Ar-
OCH3), 55.5 (Ar-OCH3), 51.9 (C-1), 40.1 (Ar-CH2-CH), 37.4 (Ar-CH2-CH2-NH), 25.0 
(Ar-CH2-CH2-NH). MS: m/z (ES+) 685 (M+H, 100 %), HRMS (ES
+): Calcd for 
C40H49N2O8 = 684.3489, found 684.3480. 
Minor isomer: 1H NMR:  6.83 (s, 1H, Ar-H-3’), 6.42 (s, 1H, Ar-H-6’), 6.09 (s, 1H, Ar-
H-5), 5.79 (s, 1H, Ar-H-8), 3.97-3.87 (m, 1H, H-1), 3.80 (s, 3H, OCH3-4’), 3.73 (s, 3H, 
OCH3-5’), 3.72 (s, 3H, OCH3-7), 3.65 (s, 3H, OCH3-6), 3.10-2.82 (m,2H, Ar-CH2-CH), 
2.74-2.67 (m, 2H, Ar-CH2-CH2-NH), 2.65-2.58 (m, 2H, Ar-CH2-CH2-NH). 
13C NMR:  
148.1 (Ar-C-OCH3-5’), 147.2 (Ar-C-OCH3-4’), 147.1 (Ar-C-OCH3-7), 146.9 (Ar-C-
OCH3-6), 133.4 (Ar-C-1’), 133.2 (Ar-C-2’), 129.4 (Ar-C-4a), 126.5 (Ar-C-8a), 113.6 
(Ar-C-H-3’), 112.9 (Ar-C-H-6’), 111.4 (Ar-C-H-8), 109.3 (Ar-C-H-5), 56.1 (C-1), 55.9 
(Ar-OCH3), 55.8 (Ar-OCH3), 55.7 (Ar-OCH3), 55.6 (Ar-OCH3), 39.3 (Ar-CH2-CH), 39.2 
(Ar-CH2-CH2-NH), 29.5 (Ar-CH2-CH2-NH). MS: m/z (ESI+) 685 (M+H, 100 %), HRMS 
(ESI+): Calcd for C40H49N2O8 = 685.3489, found 685.3480. 
 
(1RS,1’RS),(1R,1’S),PM-2,2’-[Di-{(1,2,3,4-tetrahydro-6,7-dimethoxy-2-
methylisoquinolin-1-yl)methyl}]-4,4’,5,5’-biphenyl 3  
The major isomer of 2 (8.6 mg) was dissolved in dry MeCN (0.5 mL) to which sodium 
cyanoborohydride (15 mg), 28 % formaldehyde solution (0.2 mL) and acetic acid (2 
drops) were added and the solution was stirred for 3 h. The reaction was diluted with 
CH2Cl2 (10 mL), washed with saturated aqueous NaHCO3 solution (2 x 10 mL), dried 
over anhydrous K2CO3, filtered and evaporated. Purification by silica gel 
chromatography using CH2Cl2:EtOAc:MeOH:NH3 (10:5:1:trace) as the eluent afforded 
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the title compound as an opaque film (9 mg, 96 %).  1H NMR:  6.81 (s, 1H, Ar-H-3’), 
6.38 (s, 1H, Ar-H-6’), 6.07 (s, 1H, Ar-H-5), 5.60 (s, 1H, Ar-H-8), 3.79 (s, 3H, OCH3-4’), 
3.70 (s, 3H, OCH3-5’), 3.61 (s, 3H, OCH3-7), 3.51 (s, 3H, OCH3-6), 3.38 (s, 1H, H-1), 
2.97-2.80 (m, 2H, Ar-CH2-CH), 2.77-2.63 (m, 2H, Ar-CH2-CH2-NCH3), 2.57-2.30 (m, 
2H, Ar-CH2-CH2-NCH3), 2.27 (s, 3H, NCH3). 
13C NMR:  148.0 (Ar-C-OCH3-5’), 147.5 
(Ar-C-OCH3-4’), 147.1 (Ar-C-OCH3-7’), 146.6 (Ar-C-OCH3-6’), 133.7 (Ar-C-1’), 130.0 
(Ar-C-2), 126.0 (Ar-C-4a), 125.4 (Ar-C-8a), 113.4 (Ar-C-H-6’), 113.1 (Ar-C-H-3’), 
111.2 (Ar-C-H-5), 110.7 (Ar-C-H-8), 64.1 (C-1), 56.2 (Ar-OCH3), 56.1 (Ar-OCH3), 56.0 
(Ar-OCH3), 55.8 (Ar-OCH3), 45.7 (Ar-CH2-CH), 42.9 (NCH3), 37.6 (Ar-CH2-CH2-
NCH3), 24.2 (Ar-CH2-CH2-NCH3). MS: m/z (ESI+) 713 (MH+, 100 %), HRMS (ESI+): 
Calcd for C42H53N2O8 = 713.3802, found 713.3812. 
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